Ghent University Academic Bibliography

Your filters: cql: author="Henrard, Sophie" or (type any "bookEditor issueEditor" and editor="Henrard, Sophie")

Add to list
Reply to Satapathy et al.'s comment on 'Dual cross‐sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014–2022'

Dominique Van Beckhoven, Ben Serrien, Rémy Demeester, Jens Van Praet (UGent) , Peter Messiaen, Gilles Darcis, Sophie Henrard, Paul De Munter, Agnès Libois and Jessika Deblonde

(2026) HIV MEDICINE. 27(2). p.328-331
Add to list
Belgian 2024 guidance on the use of pre-exposure prophylaxis

Jens Van Praet (UGent) , Sophie Henrard, Chris Kenyon, Agnès Libois, Annelies Meuwissen, Anne-Sophie Sauvage, Anne Vincent, Jef Vanhamel, Gert Scheerder and [missing] Belgian Research on AIDS and HIV Consortium (BREACH)

(2024) ACTA CLINICA BELGICA. 79(2). p.121-129
Add to list
- Journal Article
- A1
- open access
Understanding adaptive responses in PrEP service delivery in Belgian HIV clinics : a multiple case study using an implementation science framework

Jef Vanhamel, Thijs Reyniers (UGent) , Bea Vuylsteke, Steven Callens (UGent) , Christiana Nostlinger, Diana Huis in 't Veld (UGent) , Chris Kenyon, Jens Van Praet (UGent) , Agnes Libois, Anne Vincent, et al.

(2024) JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 27(Supplement 1).
Add to list
Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study) : results from a randomised, multicentre, controlled trial

Thibaut Vanbaelen, Achilleas Tsoumanis, Eric Florence, Christophe Van Dijck, Diana Huis in 't Veld (UGent) , Anne-Sophie Sauvage, Natacha Herssens, Irith De Baetselier, Anke Rotsaert, Veronique Verhoeven, et al.

(2024) LANCET HIV. 11(4). p.e233-e244
Add to list
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium

Rakan Nasreddine, Eric Florence, Jean Cyr Yombi, Sophie Henrard, Gilles Darcis, Jens Van Praet (UGent) , Linos Vandekerckhove (UGent) , Sabine D. Allard, Rémy Demeester, Peter Messiaen, et al.

(2023) HIV MEDICINE. 24(8). p.914-924
Add to list
- Miscellaneous
Does screening for Neisseria gonorrhoeae and Chlamydia trachomatis affect the incidence of these infections in men who have sex with men taking HIV pre-exposure prophylaxis (PrEP)Results from a randomized, multicentre controlled trial (the Gonoscreen study)

Thibaut Vanbaelen, Achilleas Tsoumanis, Eric Florence, Christophe Van Dijck, Diana Huis in 't Veld (UGent) , Anne-Sophie Sauvage, Natacha Herssens, Irith De Baetselier, Anke Rotsaert, Veronique Verhoeven, et al.

(2023) medRxiv.

Academic Bibliography

Reply to Satapathy et al.'s comment on 'Dual cross‐sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014–2022'

Belgian 2024 guidance on the use of pre-exposure prophylaxis

Understanding adaptive responses in PrEP service delivery in Belgian HIV clinics : a multiple case study using an implementation science framework

Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study) : results from a randomised, multicentre, controlled trial

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium

Does screening for Neisseria gonorrhoeae and Chlamydia trachomatis affect the incidence of these infections in men who have sex with men taking HIV pre-exposure prophylaxis (PrEP)Results from a randomized, multicentre controlled trial (the Gonoscreen study)

Contents

Support

Contact